Post Profile

Xarelto (Rivaroxaban) Recommended For Patients With Non-valvular Atrial Fibrillation, USA

Anticoagulant Xarelto (rivaroxaban) has been recommended by the FDA's Cardiovascular Renal Drugs Advisory Committee for the prevention of systemic embolism and stroke in patients with non-valvular AF (atrial fibrillation). The Committee, also known as the Panel, voted 9 to 2 in favour, with 1 abstention. The FDA (Food and Drug Administration) is expected to make a final decision on September 8th.
read more


Related Posts

For Preventing Stroke, Reducing Bleeding And Saving Lives, Apixaban Superior To Warfarin

Health : Medical News Today

A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation. Moreover, apixaban results in substantial...

Non-Valvular Artial Fibrillation Drug Xarelto® (Rivaroxaban), Studies Investigate Benefits

Health : Medical News Today

Patients with Atrial Fibrillation (AF) who undergo cardioversion or catheter ablation therapy are at particular risk of stroke and require effective anticoagulation before and after these procedures. Xarelto is indicated for the pre...

Xarelto (Rivaroxaban) Approved By FDA For Non-Valvular Atrial Fibrillation Patients

Health : Medical News Today

Xarelto (rivaroxaban), an anti-clotting medication, has been approved by the FDA for patients with non-valvular atrial fibrillation to reduce stroke risk. Xarelto, a Factor Xa inhibitor, acts at a crucial point in the blood-clotting...

Xarelto® (rivaroxaban) Gets European Green Light For DVT, Stroke And Some Types Of Atrial Fibrillation

Health : Medical News Today

CHMP, the European Committee for Medicinal Products for Human Use has approved the oral anticoagulant Xarelto (rivaroxaban) for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults. The me...

Stroke Prevention In Patients With Non-Valvular Atrial Fibrillation Using Oral Anticoagulants Including Once Daily Xarelto®

Health : Medical News Today

Once-daily oral rivaroxaban recommended by European Society of Cardiology (ESC) as a first line therapy option with a comparable efficacy and safety profile to warfarin for the prevention of stroke and systemic embolism in eligible ...


Copyright © 2016 Regator, LLC